Welcome to our dedicated page for PHARM news (Ticker: PHARM), a resource for investors and traders seeking the latest updates and insights on PHARM stock.
Pharming Group N.V. (PHARM) is a biotechnology leader developing innovative therapies for rare diseases, including hereditary angioedema (HAE) and activated phosphoinositide 3-kinase delta syndrome (APDS). This page provides investors and healthcare professionals with direct access to the company's latest press releases and official announcements.
Track PHARM's progress through updates on clinical trials, regulatory milestones, and commercialization efforts for therapies like RUCONEST® and Joenja®. Our curated news feed ensures you stay informed about earnings reports, strategic partnerships, and market expansion initiatives without extraneous information.
Discover updates categorized for quick navigation, including product development breakthroughs, financial performance disclosures, and operational strategy refinements. All content is sourced directly from Pharming's verified communications to maintain accuracy and compliance.
Bookmark this page for streamlined access to PHARM's evolving story in rare disease treatment. Check regularly for new developments that demonstrate the company's commitment to addressing unmet medical needs through biopharmaceutical innovation.
Pharming Group has announced its 2025 Annual General Meeting (AGM) scheduled for June 11, 2025. The company has nominated Dr. Elaine Sullivan as a new Non-Executive Director for a four-year term, following the departure of Deborah Jorn and Steven Baert.
The AGM agenda includes the reappointment of Jabine van der Meijs and Leonard Kruimer as Non-Executive Directors, and Deloitte Accountants as external auditor. The Board seeks authorization for share issuance and repurchase.
Dr. Sullivan brings extensive pharmaceutical and biotech experience, currently serving on boards of Zealand Pharma and hVIVO. Her background includes senior roles at Eli Lilly and AstraZeneca, plus board positions at IP Group, Evotec AG, and other companies. She holds a PhD in Molecular Virology and BSc in Molecular Biology.
Pharming Group (Euronext: PHARM/Nasdaq: PHAR) has announced multiple presentations at the 2025 Annual Meeting of the Clinical Immunology Society (CIS) in Philadelphia, scheduled for May 1-4, 2025. The presentations focus on leniolisib, including Phase III clinical data for pediatric patients aged 4-11 years with activated phosphoinositide 3-kinase delta syndrome (APDS).
The presentations include six posters covering various aspects:
- Phase 3 study outcomes of leniolisib in pediatric APDS patients
- Impact of immune dysregulation in Common Variable Immunodeficiency
- APDS-like endotype within common variable immunodeficiency
- Leniolisib's effects in autoimmune lymphoproliferative syndrome
- Demographic characteristics from the APDS-CHOIR registry
- Patient insights on APDS
Note: Leniolisib's effectiveness and safety for pediatric patients aged 4-11 years with APDS has not yet received regulatory approval.
Pharming Group (Euronext: PHARM/Nasdaq: PHAR) has announced it will release its preliminary unaudited first quarter 2025 financial results on Thursday, May 8, 2025. The results will cover the period ended March 31, 2025.
The company will host an analyst and investor presentation at 13:30 CEST/07:30 EDT on the same day. Questions will only be taken from dial-in attendees who register in advance through the provided conference call link.
Pharming Group (EURONEXT: PHARM/Nasdaq: PHAR) has received a positive recommendation from the National Institute for Health and Care Excellence (NICE) for Joenja® (leniolisib) in England and Wales. The drug is now the first and only medicine specifically approved for treating APDS (activated phosphoinositide 3-kinase delta syndrome) within the NHS.
The recommendation, based on Phase III clinical trial data, covers both adult and pediatric patients 12 years and older. The trials demonstrated significant improvements in immune deficiency and dysregulation compared to placebo, with maintained benefits during long-term treatment. The drug will be immediately available in England through the Innovative Medicines Fund, while Welsh availability is expected within three months through NHS specialist centers.
Pharming Group (Euronext Amsterdam: PHARM / Nasdaq: PHAR) has announced the filing of its Annual Report for the year ended December 31, 2024. The company has made the report accessible to investors through their website Pharming.com under the Investors/Financial documents section. Additionally, Pharming has filed its Annual Report on Form 20-F with the U.S. Securities and Exchange Commission (SEC), which will be available on both the company's website under Investors/SEC filings and the SEC website.
Pharming Group (Euronext: PHARM/Nasdaq: PHAR) has announced its participation in two major investor conferences in April 2025:
- Van Lanschot Kempen Life Sciences Conference in Amsterdam, Netherlands (April 2-3, 2025)
- 24th Annual Needham Virtual Healthcare Conference (April 7-10, 2025)
At the Needham conference, CEO Fabrice Chouraqui and CMO Anurag Relan will deliver a presentation on April 8 at 10:15 am ET/16:15 CET. The presentation will be available via live webcast and replay on Pharming's website under the 'Upcoming Events' and 'News' sections. Interested parties can schedule one-to-one meetings with management through Pharming's IR team or conference representatives.
Pharming Group has announced the dosing of the first patient in a Phase II clinical trial evaluating leniolisib for common variable immunodeficiency (CVID) with immune dysregulation. The trial is a single-arm, open-label study targeting approximately 20 patients aged 12 and older across sites in the US, UK, and EU.
The study aims to assess safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical efficacy in CVID patients with immune dysregulation. CVID represents the largest group of symptomatic primary immunodeficiency patients, with a global prevalence of approximately 39 patients per million for the targeted population.
Led by Dr. Jocelyn Farmer at Beth Israel Lahey Health, the trial focuses on patients with CVID diagnosis, lymphoproliferation evidence, and additional immune dysregulation manifestations. CVID patients with immune dysregulation face an 11-fold higher mortality rate compared to those with infectious manifestations alone. Leniolisib, currently marketed as Joenja® in the U.S. for APDS treatment, represents a potential therapy for this unmet medical need.
Pharming Group reported strong financial results for Q4 and full year 2024, with total revenues increasing 21% to US$297.2 million, exceeding guidance. This growth was driven by record RUCONEST® revenue of US$252.2 million (up 11%) and strong Joenja® performance of US$45.0 million (up 147%).
Q4 2024 highlights include total revenues of US$92.7 million (up 14%) and operating profit increase to US$6.7 million from US$1.1 million in Q4 2023. The company generated operating profit and positive cash flows for two consecutive quarters.
Key developments include two ongoing Phase II trials of leniolisib for additional primary immunodeficiencies, the completion of Abliva AB acquisition adding KL1333 to the pipeline, and the appointment of Fabrice Chouraqui as CEO. The company provided 2025 revenue guidance of US$315-335 million.
Pharming Group (EURONEXT: PHARM/Nasdaq: PHAR) announced that shareholders approved all proposals at their Extraordinary General Meeting (EGM). Fabrice Chouraqui has been appointed as Executive Director and Chief Executive Officer for a four-year term, effective immediately. He succeeds Sijmen de Vries, who will remain as a strategic advisor until December 31, 2025, to ensure a smooth transition.
Shareholders also approved specific components of Chouraqui's remuneration package. The company has made available a recording of the webcast and presentation slides from the EGM on their website's Investor Relations section.
